论文部分内容阅读
以去甲基万古霉素产生菌Ｂ３７和替考拉宁类抗生素产生菌Ｅ９２－７０为出发菌株，将Ｂ３７原生质体热灭活，进行属间原生质体融合，融合率为１．４×１０~（－６）～４．６×１０~（－６），融合子５０％以上抗菌活性增强。对融合子Ｅ９作了深入研究，其抗ＭＲＳＡ活性明显增强，纸层谱、ＨＰＬＣ图谱以及总ＤＮＡ的ＳａｌＩ酶切图谱与两亲本均有差异，Ｅ９在分类上仍与Ｅ９２－７０同属，其产物为胞壁抑制物，作用点仍在细菌胞壁Ｄ－Ａｌａ－Ｄ－Ａｌａ上，Ｅ９很可能是Ｂ３７与Ｅ９２－７０的重组子，其产物可能是不同于去甲基万古霉素和替可拉宁的新的糖肽类杂合抗生素。
B37 protoplasts were heat inactivated by intergenic protoplast fusion with demethyl vancomycin producing bacteria B37 and teicoplanin antibiotic producing bacteria E92-70 as the starting strain, the fusion rate was 1.4 × 10 ~ (-6) ~ 4.6 × 10 ~ (-6), and the antimicrobial activity of the fusion protein was enhanced more than 50%. The fusion molecule E9 was studied in depth and its anti-MRSA activity was significantly enhanced. The paper also showed that the E9 was still classified as E92-70 in the paper by TLC, HPLC and SalI digestion. Is a cell wall inhibitor, the site of action is still on the bacterial cell wall D-Ala-D-Ala, E9 is likely to be a recombinant of B37 and E92-70, the product may be different from norme vancomycin and for Ranin’s new glycopeptide-based hybrid antibiotics.